<< Go back to the Podcast page EPISODE 55 - NEN Treatment Sequencing & Strategy Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this episode, medical oncologist Dr. Chandrikha Chandrasekharan from MD Anderson Cancer Center breaks down how treatment decisions are made and sequenced for patients with neuroendocrine neoplasms (NENs). The conversation explores what “benign” and “indolent” really mean, how treatment goals are defined, and how clinicians balance effectiveness, side effects, and long-term strategy. Dr. Chandrasekharan discusses sequencing therapies without burning bridges, when treatments can be reused, how prior response informs future decisions, and when to consider clinical trials. The episode emphasizes shared decision-making, aligning treatment plans with patient values, and navigating care with clarity rather than fear. TOP TEN QUESTIONS 1. Is Neuroendocrine Cancer ever “benign”? What does “benign” actually mean in the context of neuroendocrine tumors? When might a tumor be considered benign, and when is it clearly malignant? Can neuroendocrine cancer be “cured”? How should patients understand tumor behavior if they’ve been told theirs is slow-growing or “indolent”? 2.What is the real goal of treatment? Can I go into “remission”? Is it to make all the tumors disappear? Many patients describe feeling like they have a ticking time bomb inside them. Can you speak to that fear and how treatment goals are set? 3.Which treatment works “the best”? How do we even define “best” when it comes to neuroendocrine cancer? 4. Which treatments tend to have the fewest side effects? How should patients think about balancing effectiveness with quality of life? 5. How can someone know which treatment is right for their type of neuroendocrine cancer and their current situation? What factors matter most? 6. Is there a “best way” to sequence treatments? How do patients and clinicians prioritize options in a way that doesn’t “burn bridges” for the future? How do age, gender, race, and ethnicity influence treatment decisions, if at all? 7. If a treatment worked well for me before, is it possible to use it again? If a treatment does not work well, what does that mean? Does it predict how I might respond to another therapy? Does it imply anything about my overall prognosis? 8.What are the “big guns,” and when should they be used? Is there such a thing as “wasting” a treatment? 9. When should someone consider clinical trials? Should clinical trials be considered only after standard treatments, or earlier? 10. What advice do you have for people who receive differing opinions from their provider(s)? Bonus: What advice do you have for patients in communicating their values and preferences with their providers? MEET DR. CHANDRIKHA CHANDRASEKHARAN Chandrikha Chandrasekharan, MD Gastrointestinal Medical Oncologist MD Anderson Cancer Center Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine. Dr. Chandrasekharan earned her medical degree from Kilpauk Medical College in India. She completed her internal medicine residency at the University of Florida College of Medicine in Jacksonville, followed by a fellowship in Palliative Medicine at Mayo Clinic, Rochester. She then pursued a fellowship in Medical Oncology at LSU Shreveport, and further specialized in gastrointestinal malignancies with an additional year of training at Mayo Clinic, where she developed a strong interest in neuroendocrine tumors. Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-led the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care. RESOURCES WATCH https://www.youtube.com/watch?list=PLPAgUIq-85n_3uy-Uc79Uk7rTxnD4j1x0&v=B77clXPk08w Dr. Chandrasekharan: "Understanding NET Diagnosis: The Work-Up & What You Need to Know About Your NETs" (2024 Neuroendocrine Tumor Patient Conference) DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Back Targeted Therapies Oral Targeted Therapies STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Antibody Drug Conjugate (ADC) Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IDE849 (DLL3-Targeted ADC) ± Durvalumab in DLL3+ Tumors ZL-1310 (DLL3-targeted ADC) in DLL3+ Tumors DLL-3 DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Join NCF for Apr2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Cdk8uoqKWe0 Learn about the latest in clinical trials for neuroendocrine cancer with NET expert Dr. Heloisa Soares, a medical oncologist at the Huntsman Cancer Institute (HCI) at the University of Utah. ABOUT DR. HELOISA SOARES Dr. Heloisa Soares is a medical oncologist who focuses on neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at the University of Utah, where she is also the Medical Director for the Clinical Trials Office. Nationally, she serves as the NCI NET task force co-chair and the chair of the North American Neuroendocrine Tumor Society (NANETS) inaugural NET Patient Action Team of the NETPact Committee. She also recently served as a member of the directors for NANETS. Dr. Soares is a passionate advocate for patients. You can follow her on Twitter at @helops79. SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Explore lanreotide and octreotide resources for neuroendocrine tumor patients, including injections, patient support, copay assistance and education. Lanreotide & Octreotide Resources for Neuroendocrine Tumors SOMATULINE DEPOT (LANREOTIDE) RESOURCES Somatuline Depot Downloadable Patient Support Guides Somatuline Depot (Lanreotide) Copay Assistance/Home Injections: Click here to learn more , OR CALL (866) 435-5677 Ipsen - GEP-NETs Network - Injection Map SANDOSTATIN LAR DEPOT (OCTREOTIDE) RESOURCES Novartis - Patient Resources Novartis - Universal Copay Program Patient Assistance Now Oncology Sandostatin LAR Depot (Octreotide) Copay Assistance: Novartis - Patient Assistance Foundation Enrollment Novartis - Universal Copay Program or call 1-800-277-2254 READ LACNETS Blog Post - "A Focus on Somatostatin Analogs (Your Monthly Shots)" LACNETS Blog Post - "The Shot" LACNETS Blog Post - "Practical Tips for Patients on the Shot Somatostatin Analog" LISTEN Podcast Episode 32: Focus on Somatostatin Analogues (SSAs)

Lu-177 DOTATATE + Olaparib in GEP-NETs << Back Lu-177-DOTATATE in Combination With Olaparib in Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT04086485 DRUG/TREATMENT: Lu-177 DOTATATE + OLAPARIB PHASE I / II STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=CC2NXP21R24 Dr. Del Rivero discusses Lu177-Dotatate + OLAPARIB DESCRIPTION: This phase 1-2 trial tests Lu-177-DOTATATE (Lutathera) in combination With olaparib (PARP inhibitor) in inoperable gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). The objective is to learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lu-177 DOTATATE and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Frank Lin, MD CONTACT: National Cancer Institute Joy Zou, RN EMAIL: joy.zou@nih.gov PHONE: 240-760-6153

MONTHLY Virtual NET Caregiver Support Group Meetings Monthly on a Saturday (Scroll down for specific dates) 8:00 - 10:00 AM Pacific Register 2026 Dates: Jan 31, 2026 Feb 28, 2026 Mar 28, 2026 Apr 25, 2026 May 30, 2026 Jun 27, 2026 Jul 25, 2026 Aug 29, 2026 Sep 19, 2026 Oct 24, 2026 Nov 21, 2026 Dec 19, 2026 Neuroendocrine Cancer Foundation's Monthly NET Caregiver-Only support group is a virtual space to come together for support, connection and community with other care partners who support, or have supported, those with Neuroendocrine Cancer. Unlike our Weekly Wednesday Support Group for Caregivers & Patients that focuses on medical aspects of NETs, this group focuses on the unique experiences and psycho-social concerns of caregivers. *OPEN TO NET CAREGIVERS ONLY. The zoom link is provided in the RSVP confirmation (received immediately after registration) and will also be emailed to you monthly from Heather@NCF.net prior to the meeting. Questions? Need technical support? Email events@ncf.net . THANKS TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 1: NUTRITION FOR NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE For our very first episode, we welcome NET Dietician Meghan Laszlo, MS, RD, CSO of Cedars-Sinai Medical Center. Meghan answers the top 10 NET nutrition questions, covering topics including carcinoid syndrome, prescription enzymes, diarrhea, recommended diet for NET patients, and much more! MEET MEGAN LASZLO Meghan Laszlo is a Registered Dietitian (R.D.) and a Board-Certified Specialist in Oncology Nutrition (C.S.O.) at Cedars Sinai’s Samuel Oschin Cancer Center. As an outpatient dietitian, she provides medical nutrition therapy to patients through nutrition counseling, education, and coordination of care. Meghan is fascinated by the nutritional aspects of gastrointestinal, neuroendocrine, and head and neck cancers and is dedicated to helping patients meet their individualized goals. In October 2019, Meghan gave a presentation for LACNETS titled "Nutrition for NETs." Watch the full video here >> TOP NET NUTRITION QUESTIONS 1. What kind of diet benefits NET patients? 2. Which foods cause carcinoid syndrome symptoms? 3. Which foods make diarrhea better and worse? 4. What kinds of fluids and how much are needed with diarrhea? 5. Which dietary supplements are beneficial for NET patients? 6. What is niacin and why is it important for individuals with carcinoid syndrome? 7. How does fat malabsorption effect digestion? 8. How do I know if the pancreatic enzymes are working? 9. What is small intestinal bacterial overgrowth (SIBO)? DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANKS TO OUR SPONSORS

CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen << Back CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen IDENTIFIER ( ClinicalTrials.gov ) : NCT07087054 DRUG/TREATMENT : Paltusotine PHASE : 3 STATUS : Recruiting SPONSOR : Crinetics Pharmaceuticals Inc. https://www.youtube.com/watch?v=b6Jnzj9Epng CAREFNDR Presentation Slides .pdf Download PDF • 1.60MB DESCRIPTION: A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differentiated neuroendocrine tumors. The purpose of this study is to continue the evaluation of the safety, efficacy, and pharmacokinetics (PK) of paltusotine in participants with carcinoid syndrome. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. MORE INFORMATION Download the CAREFNDR flyer here >>> For more information about the CAREFNDR clinical study, visit CAREFNDR.com/ncf . Global enrollment in CAREFNDR is expected throughout 2025 and 2026. Read this recent press release: " Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome" CONTACT Crinetics Clinical Trials EMAIL: clinicaltrials@crinetics.com PHONE: 833-276-4636 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

<< Back Pheochromocytoma/ Paraganglioma Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Belzutifan/MK-6482 in PNET + PPGL + VHL BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Olaparib + Usual Chemotherapy (Temozolomide) in PPGL NETTER-P: Lutathera in Adolescent Patients LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Learn about neuroendocrine cancer and the importance of awareness. Get essential information and resources to support those affected by NET cancer. Neuroendocrine Cancer Awareness and Information LEARN MORE Why is neuroendocrine cancer easily missed? Learn the facts. Read More > NET CANCER DAY Learn what you can do to raise awareness. Read More > FOR HEALTHCARE PROVIDERS Learn more about professional medical organizations, CMEs, research grants, and conferences available for healthcare providers. Read More > About NET ABOUT NET On average it takes 5-7 years to accurately diagnose NET. Neuroendocrine cancer affects men, women & children. It does not discriminate. NETs can be easily mistaken for IBS, gastritis, anxiety & asthma. NETs are more common than brain, ovarian or cervical cancer. Due in part to the rarity of the disease, NETs are often misdiagnosed. Approximately 50% of NETs have already spread to other parts of the neuroendocrine system when the diagnosis is made. 1/3 of NET patients are diagnosed incidentally while testing for another condition. NET CANCER DAY NET Cancer Day is an annual event held on the 10th of November, created by the International Neuroendocrine Cancer Alliance (INCA) to increase awareness of neuroendocrine cancers (NETs) and to provide a voice to the NET community. On November 10th, INCA members, including the Neuroendocrine Cancer Foundation, from around the globe, promote resources to increase awareness about this often misdiagnosed cancer. You can join this global community to raise awareness for NETs around the world. On Nov 10th, download an image below and post it on your social media or share it via email. For more tools and resources about NET Cancer Day, visit the INCA campaign page . NET Cancer Day HealthCare Providers FOR HEALTHCARE PROVIDERS The North American Neuroendocrine Tumor Society (NANETS) is dedicated to educating medical professionals on the diagnosis and treatment of NET disease and supporting research and innovation in the field. NANETS provides the following educational programs, CMEs and resources for medical providers: Regional NET education programs Monthly virtual education programs Annual NET Medical Symposium NETCAST podcast NET Guidelines to support the treatment and management of NET Go to nanets.net/ to learn more. The International Neuroendocrine Cancer Alliance’s mission is to be the global advocate for neuroendocrine cancer patients. INCA provides NET patient information packs in 11 languages for patients, health professionals, and anyone wanting to better understand NETs. The Think NENs Global Educational Program for Primary Care Physicians is a free, comprehensive e-learning program that provides everything primary care physicians need to know about diagnostics, treatment, and care of patients with neuroendocrine cancer. The 1-hour main module of three videos (each 20 minutes long) provides UEMS-EACCME® credit if the enclosed exam is completed successfully. Providers can register here: https://thinknensinprimarycare.incalliance.org/ Download & print brochures to bring to your providers. Go to incalliance.org to learn more. The American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO provides: Learning opportunities for oncology professionals Global network of oncology expertise Meetings & educational opportunities, including ASCO Gastrointestinal Cancers Symposium Guidelines for Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Go to https://asco.org/ to learn more. The Neuroendocrine Cancer Foundation supports neuroendocrine cancer patients & caregivers. Below are some of the resources the Neuroendocrine Cancer Foundation provides: Clinical Trials Guide Blog Resources by Topic Video Library Go to Home Page

In an effort to raise awareness about neuroendocrine cancer (NETs) in the healthcare community, we invite you to use YOUR voice, take the pledge, and join the #AskMeABoutNETs Challenge. The #AskMeAboutNETs Challenge In an effort to raise awareness about neuroendocrine cancer (NETs) in the healthcare community, we invite you to use YOUR voice, take the pledge, and join the #AskMeABoutNETs Challenge. What is the #AskMeABoutNETs Challenge? LACNETS is inspiring NET patients and allies around the world to educate their local healthcare professionals about NETs. Ready for your challenge?! We ask you to take the pledge to educate two or more of your local healthcare professionals using our #AskMeAboutNETs downloadable packets (included below). To complete the challenge, you must follow these four simple steps: Step 1: Take the pledge by clicking “take the pledge” button below. Step 2: Download the #AskMeAboutNETs information packet (included below). Step 3: Personally deliver, mail, or email the #AskMeAboutNETs information packet to at least TWO of your local health professionals. Step 4: Complete the “challenge completion form” at the bottom of this page to confirm you have completed steps 1 and 2. TAKE THE PLEDGE First Name Last Name Email TAKE THE PLEDGE Thanks for taking the pledge! Why is this challenge important? One of the biggest and most urgent challenges for the NET community is the lack of information throughout our local healthcare systems. It’s vital that we do our part to educate our local healthcare communities which can lead to earlier diagnosis and expanded research. The more of us who take the pledge, the more healthcare professionals will be reached. Our voices are stronger together! What’s in the #AskMeAboutNETS packet? To make your outreach easier, we put together downloadable packets for both patients and allies, which include: An introductory letter (from a NET patient or NET ally ) Facts about NET Symptoms of NET Resources for patients and caregivers Resources for healthcare professionals Information about NET Cancer Day (a day dedicated to increasing awareness of NET) (If you have any issues downloading the packet, please contact events@LACNETS.org.) #AskMeAboutNETs Downloadable Packets Download this packet if you are a NET patient. DOWNLOAD THE PATIENT PACKET Download this packet if you are an ally to a NET patient. DOWNLOAD THE ALLY PACKET CHALLENGE COMPLETION FORM Please complete this form after you have shared the #AskMeAboutNETs with two healthcare professionals. #AskMeAboutNETs Completion Form First Name Last Name Email Health Care Professional #1 - Please share name, title/type of health care professional, institution or clinic Health Care Professional #2 - Please share name, title/type of health care professional, institution or clinic SUBMIT Thanks for submitting!

<< Go back to the Podcast page EPISODE 33: FOCUS ON TARGETED THERAPIES Download a Transcript of this Episode >>> ABOUT THIS EPISODE What are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter’s invisibility cloak in understanding treatment goals with NETs. MEET DR. SCOTT PAULSON Dr. Paulson is a medical oncologist and the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He also serves as the co-director of the Gastrointestinal Research Program for the Sarah Cannon Research Institute. Dr. Paulson earned his medical doctorate at The University of Texas Southwestern Medical School. He took his residency and an internship in internal medicine at Brigham and Women's Hospital in Boston, Massachusetts. His fellowship was completed in medical oncology at the University of California, San Francisco. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. He currently is an investigator on a clinical trial studying nab-sirolimus, a mTOR inhibitor, which is a type of targeted therapy. TOP TEN QUESTIONS ABOUT TARGETED THERAPIES FOR NETs: What are targeted therapies? Are they considered chemotherapy? How do they work? What are the different types of targeted therapies for NETs? When and how are targeted therapies used? What side effects might someone have when taking a targeted therapy? Can targeted therapies affect blood sugars or cause diabetes? Can targeted therapies cause one to be immunocompromised? Can targeted therapies affect one’s blood counts? What is the goal of treatment with targeted therapies? (Why would one take these drugs given the potential side effects? Can the side effects be managed?) How do you decide which targeted therapy to recommend for a patient? Can a NET patient take more than one drug in this category? Can the medications be stopped and restarted? What is your approach with dosing? What is your approach with monitoring? What and how often do people need blood work? Does taking a targeted therapy preclude someone from getting another treatment in the future, such as Lutathera/PRRT, or a clinical trial of alpha PRRT? BONUS: What are the latest advances in targeted therapy? What is the future of targeted therapies? RESOURCES WATCH https://www.youtube.com/watch?v=OCtGElKt_J4 March 2024 LACNETS Educational Event with Dr. Jennifer Chan: "TKIs: Tyrosine Kinase Inhibitors & Neuroendocrine Tumors" https://www.youtube.com/watch?v=VuCnxQKJlSc 2023 LACNETS Neuroendocrine Tumor Patient Education Conference with Dr. Pamela Kunz: "The Latest in Systemic Treatments & Considerations for Treatment Sequencing" https://www.youtube.com/watch?v=VonfcmeellU October 2023: Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib CLINICAL TRIALS MENTIONED IN THIS EPISODE CABINET Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced NETs After Progression on Prior Therapy Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS